CPRX
Catalyst Pharmaceuticals Inc

15,798
Mkt Cap
$2.57B
Volume
1.29M
52W High
$26.58
52W Low
$19.05
PE Ratio
12.72
CPRX Fundamentals
Price
$20.97
Prev Close
$21.43
Open
$21.44
50D MA
$20.30
Beta
1.01
Avg. Volume
1.7M
EPS (Annual)
$1.31
P/B
3.00
Rev/Employee
$2.72M
Loading...
Loading...
News
all
press releases
Why Catalyst Pharmaceutical (CPRX) is a Top Momentum Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Zacks·13d ago
News Placeholder
More News
News Placeholder
Why Catalyst Pharmaceutical (CPRX) is a Top Growth Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Zacks·15d ago
News Placeholder
Why Catalyst Pharmaceutical (CPRX) is a Top Growth Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Zacks·1mo ago
News Placeholder
Catalyst Pharmaceutical (CPRX) is a Top-Ranked Value Stock: Should You Buy?
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Zacks·1mo ago
News Placeholder
Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Value Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Zacks·2mo ago
News Placeholder
Catalyst Pharmaceuticals Settles Firdapse Patent Litigation With Lupin
CPRX secures a key win as its Firdapse patent litigation settlement with Lupin shields U.S. sales from generic competition until 2035.
Zacks·2mo ago
News Placeholder
Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Growth Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Zacks·2mo ago
News Placeholder
Why Catalyst Pharmaceutical (CPRX) is a Top Value Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Zacks·2mo ago
News Placeholder
Catalyst Pharmaceuticals Q2 Earnings Beat, Firdapse Revenues Rise Y/Y
CPRX beats Q2 earnings and revenue estimates as Firdapse and Agamree drive strong top-line growth.
Zacks·3mo ago
News Placeholder
Rigel Pharmaceuticals, Inc. (RIGL) Hits Fresh High: Is There Still Room to Run?
Rigel (RIGL) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Zacks·3mo ago

Latest CPRX News

View

Advertisement|Remove ads.

Advertisement|Remove ads.